Hematology-Oncology
Latest news
304 articles · 20 / page
Pilot Study: Busulfan-Based Haploidentical Stem Cell Transplantation Plus GD2 Antibody Therapy for High-Risk Neuroblastoma
A small pilot study found that busulfan-based haploidentical stem cell transplantation followed by dinutuximab beta was feasible and may improve long-term remission in very high-risk neuroblastoma.
S1P Receptor Modulation Restores FLT3 Inhibitor Sensitivity in NRAS-Mutated FLT3-ITD Acute Myeloid Leukemia
Preclinical data suggest fingolimod and mocravimod can resensitize NRAS-mutated FLT3-ITD AML to FLT3 inhibitors by suppressing ERK-SPHK1-AKT signaling, including activity in patient blasts and an orthotopic mouse model.
Application of the AHA-Proposed Cancer-Related Ischemic Stroke Classification: Reclassification and Prognostic Impact
The AHA-proposed CRIS classification reclassified many cancer-associated strokes previously labeled cryptogenic and identified a subgroup with markedly worse survival, improving both etiologic clarity and prognostic stratification.
Early High-Resolution Immune Profiles Are Linked to Survival and Relapse After Allogeneic Stem Cell Transplantation
Early immune profiling after allogeneic stem cell transplant was linked to survival and relapse risk. Stronger innate and adaptive immune recovery predicted better outcomes, while certain activation and checkpoint markers were associated wi
Twice-Weekly All-Oral Ixazomib, Pomalidomide, and Dexamethasone Shows Durable Activity in Relapsed/Refractory Multiple Myeloma
A phase I/II study suggests twice-weekly ixazomib plus pomalidomide-dexamethasone is a feasible all-oral option in relapsed/refractory multiple myeloma, with a 65.8% response rate at the RP2D and manageable hematologic toxicity.
Cellular and Molecular Mechanisms of Relapse After CD19/CD22 Dual-Target CAR T-Cell Therapy in B-Cell Acute Lymphoblastic Leukemia
A study of 91 B-ALL patients found that relapse after CD19/CD22 dual-target CAR T-cell therapy is mainly driven by CAR T-cell functional failure and antigen loss, with PAX5 mutations linked to early immune escape.
Anti-CD117 Conditioning With Briquilimab Shows Feasibility and Stem-Cell Depletion in Older Adults Undergoing Allogeneic Transplant for High-Risk AML and MDS
A phase 1 trial suggests briquilimab can be safely added to nonmyeloablative conditioning before allogeneic transplant in older adults with high-risk AML or MDS, with biologic evidence of hematopoietic stem/progenitor cell depletion and enc
EBMT Crosses One Million Transplants as Allogeneic HCT and CAR-T Reach New Highs in European Cellular Therapy
The 2024 EBMT activity report marks a major cellular therapy milestone, showing record allogeneic HCT, continued CAR-T expansion, and persistent disparities in donor use, pediatric activity, and country-level access.
The 2024 EBMT Activity Report: Crossing One Million HCTs and 20,000 CAR-T, a Landmark in Cellular Therapy
EBMT’s 2024 report marks over one million reported stem cell transplants and continued rapid CAR-T growth, highlighting shifts in indications, donor use, and access across Europe.
Next-Generation Sequencing MRD Detection Predicts Outcomes in AML Patients Undergoing Allogeneic Stem Cell Transplantation
A low-cost NGS-based MRD test detected hidden AML cells before transplant and strongly predicted worse survival after allogeneic stem cell transplantation.
Targeting Ibrutinib Resistance Pathways with miR-28 in ABC-DLBCL
miR-28 suppresses the emergence of ibrutinib resistance in ABC-DLBCL by disrupting clonal selection and dampening mitochondrial and mTOR signaling, with promising preclinical nanoparticle delivery results.
Regulatory-like FOXP3+Helios+CD4+ T Conventional Cells Correlate with T-Cell Activation After Orca-T Immunotherapy
A study of leukemia patients found that Orca-T transplant therapy increases a regulatory-like CD4+FOXP3+Helios+ T-cell subset early after treatment, and this subset correlates with later T-cell activation, offering a potential biomarker for
Elevated Von Willebrand Factor and Factor VIII Show Promise as Biomarkers for Diagnosis and Monitoring of Chronic Graft-Versus-Host Disease
In a prospective cohort, VWF and FVIII were significantly elevated in chronic graft-versus-host disease, tracked with disease activity, and showed moderate diagnostic performance for early cGvHD.
Activity of PROTAC MDM2 Degrader in Primary Leukemia Cells and PDX Models
MD-265, a PROTAC MDM2 degrader, showed strong anti-leukemia activity in primary AML cells and mouse PDX models, outperformed a conventional MDM2 inhibitor, and spared normal stem cells relatively well.
Self-Reinforcing IL-1β Signaling Accelerates TCF3::HLF-Positive B-ALL Development and Relapse
Researchers found that IL-1β signaling drives growth, relapse, and bone damage in TCF3::HLF-positive B-ALL, suggesting IL-1β blockade may offer a new treatment strategy.
Safety and Effectiveness of Rivaroxaban Thromboprophylaxis in ACTH-Dependent Cushing Syndrome
Routine oral rivaroxaban prophylaxis in ACTH-dependent Cushing syndrome was associated with no new VTE events after implementation and no bleeding complications, suggesting it is a safe and effective preventive strategy.
Diagnostic Performance of Anti-Epstein-Barr Virus BNLF2b in Suspected Nasopharyngeal Carcinoma
P85-Ab, an anti-EBV BNLF2b antibody test, showed excellent accuracy for suspected nasopharyngeal carcinoma and outperformed older EBV markers in most outpatient settings.
Frontline Allogeneic Transplantation Outperforms Pretransplant IPSS-M Downstaging in Myelodysplastic Neoplasms
In adults with myelodysplastic neoplasms undergoing allogeneic transplantation, pretransplant cytoreduction modestly improved IPSS-M in some patients but did not improve post-transplant survival and was associated with higher non-relapse mo
Choosing a Stem Cell Donor: Why Age Matters More in Some Transplants Than Others
A major 2026 study suggests donor age affects survival differently in haploidentical and matched unrelated stem cell transplants, offering a more practical framework for choosing the best donor.
CBFB::MYH11 MRD After the Second Chemotherapy Cycle: A Guide to Allogeneic Transplantation in Favorable-Risk AML
Post-cycle 2 CBFB::MYH11 MRD best predicted outcomes in favorable-risk AML. Patients with levels ≥1% had higher relapse risk, and those receiving allo-HCT in CR1 had better 3-year disease-free survival than chemotherapy consolidation.
Browse by specialty
Open language-specific specialty feeds and department pages.